| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8680315 | Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | 2017 | 10 Pages |
Abstract
The high accuracy of either CERAD criteria suggests that [18F]flutemetamol predominantly reflects neuritic amyloid plaque density. However, the use of CERAD criteria as the SoT can result in some false-positive results because of the presence of diffuse plaques, which are accounted for when the positron emission tomography read is compared with the 2012 NIA-AA criteria.
Related Topics
Life Sciences
Neuroscience
Neurology
![Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease](/preview/png/8680315.png "First Page Preview: Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease")
Authors
Stephen Salloway, Jose E. Gamez, Upinder Singh, Carl H. Sadowsky, Teresa Villena, Marwan N. Sabbagh, Thomas G. Beach, Ranjan Duara, Adam S. Fleisher, Kirk A. Frey, Zuzana Walker, Arvinder Hunjan, Yavir M. Escovar, Marc E. Agronin, Joel Ross,